Table 2.

Baseline characteristics associated with prevalent or incident GC, CT or combined CT/GC infection

	CT/GC		CT		GC
	Univariate RR (95% CI)	Multivariable RR (95% CI)	Univariate RR (95% CI)	Multivariable RR (95% CI)	Univariate RR (95% CI)	Multivariable RR (95% CI)
Baseline infection
Site
Cape Town vs Harare	2.10 (1.38, 3.18)	2.38 (1.35, 4.19)**	1.96 (1.26, 3.06)	2.41 (1.31, 4.43)**	2.76 (1.22, 6.22)	2.28 (0.88, 5.89)
Johannesburg vs Harare	1.46 (0.96, 2.26)	1.13 (0.67, 1.91)	1.52 (0.96, 2.40)	1.27 (0.73, 2.22)	0.68 (0.24, 1.98)	0.52 (0.15, 1.84)
Age (years)*					0.86 (0.72, 1.02)	0.95 (0.79, 1.14)
Living arrangements
Lives with partner vs parents and/or siblings	0.54 (0.20, 1.44)	0.85 (0.44, 1.64)	0.84 (0.54, 1.34)	1.01 (0.51, 1.98)
Lives with other vs parents and/or siblings	0.68 (0.28, 1.66)	1.87 (1.13, 3.08)*	1.34 (0.90, 1.98)	1.93 (1.14, 3.27)*
Modified risk score*					1.34 (0.96, 1.84)	1.25 (0.87, 1.79)
No of vaginal sex acts, past month*					1.04 (1.00, 1.06)	1.03 (1.00, 1.06)*
Condom use at last sex	0.66 (0.46, 0.98)	0.67 (0.45, 0.99)*	0.68 (0.46, 1.02)	0.69 (0.46, 1.05)
Incident infection
Site
Cape Town vs Harare	1.60 (1.08, 2.36)	1.14 (0.70, 1.86)	1.50 (0.94, 2.42)	1.39 (0.78, 2.48)	2.20 (1.12, 4.34)	2.40 (1.18, 4.90)*
Johannesburg vs Harare	0.96 (0.62, 1.48)	0.56 (0.31, 1.00)*	1.22 (0.76, 1.98)	0.87 (0.48, 1.56)	0.14 (0.04, 0.64)	0.15 (0.33, 0.70)*
Age (years)*			0.94 (0.86, 1.00)	1.01 (0.91, 1.11)
CES-D score*	1.02 (1.00, 1.06)	1.02 (0.99, 1.05)	1.04 (1.02, 1.08)	1.05 (1.01, 1.09)**	1.00 (0.94, 1.06)	1.00 (0.95, 1.06)
Age difference of primary partner	0.94 (0.88, 1.00)	0.94 (0.88, 1.01)	0.94 (0.88, 1.02)	0.95 (0.88, 1.02)
Long-acting contraceptive use (baseline)†			1.42 (0.92, 2.18)	1.18 (0.69, 2.03)
Anal sex, past month
Yes vs no	1.18 (0.74, 1.90)	1.34 (0.76, 2.33)
Prefer not to answer vs no	0.70 (0.50, 0.98)	0.75 (0.49, 1.15)
CT/GC at baseline	1.66 (1.20, 2.32)**	1.66 (1.12, 2.45)*
CT at baseline			1.84 (1.26, 2.66)	2.01 (1.28, 3.15)**
Detectable TFV-DP‡	1.00 (0.73, 1.35)		0.78 (0.54, 1.13)		1.46 (0.86, 2.49)
TFV-DP ≥700 fmol/punch‡	1.00 (0.63, 1.58)		0.76 (0.43, 1.34)		1.96 (0.98, 3.91)	2.04 (1.02, 4.08)*

*P<0.05, **p<0.005.

*Continuous variables.

†Long-acting reversible contraceptive includes injectables, implants and intrauterine devices.

‡Based on DBS collected at month 6 and/or 12.

CES-D, Center for Epidemiological Studies Depression; CT, Chlamydia trachomatis; DBS, dried blood spots; GC, Neisseria gonorrhoeae; RR, relative risk; TFV-DP, tenofovir-diphosphate.